Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021

  • Published: May 2017
  • Pages: 70
  • SKU: IRTNTR12755

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

This industry research report identifies Pfizer, Merck, Novartis, GlaxoSmithKline, Teva Pharmaceutical Industries, and Mylan as the key vendors in the global hospital-acquired pneumonia (HAP) drugs market. This industry research report also presents a competitive analysis of the market by drug type (antibacterial, antiviral, and antifungal) and by geography (the Americas, APAC, and EMEA).

Hospital-acquired pneumonia (HAP) drugs market

Market research analysts at Technavio predict that the global hospital-acquired pneumonia (HAP) drugs market will grow steadily during the forecast period and post a CAGR of more than 2% by 2021. This market research analysis identifies the inadequate healthcare infrastructure in the developing countries as one of the primary growth factors for this market.

HAP drugs market drivers

The inadequate healthcare infrastructure and the lack of proper hygiene in developing countries are the major problems which lead to healthcare-associated infections. Infection control procedure and other hygienic necessities are influenced by several factors such as poor infrastructure, the lack of financial resources, and overcrowded hospitals. Inadequate sanitary conditions and the inappropriate use of sanitary drugs are some of the artificial factors leading to the development of MDR microorganisms, consequently rising HAP cases. This will increase the need for HAP drugs, which will, in turn, augment the growth prospects for the HAP drugs market.

HAP drugs market trends

The market research report identifies the emergence of combination therapy for the treatment of HAP as one of the key trends behind the growth of the HAP drugs market. Monotherapy is deemed to be the common treatment for pneumonia but it has been observed that combination treatment provides better results and is the appropriate and desirable treatment. The increased resistance of pathogens to the administered drug triggers the demand and implementation of combination drugs. Combination therapy reduces the chances of resistance developed by the bacteria and provides a broad spectrum of coverage, consequently propelling the growth of the market.

HAP drugs market: Competitive landscape and key vendors

The HAP drugs market is fragmented due to the presence of vendors of various sizes and market shares. It is dominated by few key players that set competitive pricing strategies followed in the market. The vendors in the market mainly compete based on the pricing strategies and the product portfolio offered to customers. Increased investments in R&D and M&A will impact the vendors’ performance and also the market’s competitive environment.

The leading vendors in the HAP drugs market

  • GlaxoSmithKline
  • Merck
  • Mylan
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries

HAP drugs market  segmentation by drug type 

  • Antibacterial
  • Antiviral
  • Antifungal

Bacteria is the major cause of HAP and there are numerous players in the market who produce antibacterial drugs mainly due to the availability of generic versions of the drugs. According to this market research report, the antibacterial segment accounted for the major shares and dominated the HAP drugs market during 2016. Factors such as the increased usage of antibacterial drugs for the prevention and treatment of bacterial infections will contribute to the growth of this market segment in the coming years.

HAP drugs market based on geographical segmentation

  • Americas
  • APAC
  • EMEA

This market study estimates that in terms of geographic regions, the Americas will be the major revenue contributor to the market by 2021. This is mainly due to the high prevalence of pneumonia and hospital acquired infection and the relevant steps taken by the governments of countries in this region. Additionally, the presence of numerous key vendors that has enabled easy access and has improved the quality of treatment available to the consumers, will also fuel the growth prospects of the HAP drugs market in this region.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2021?
  • What are the key factors driving the global hospital-acquired pneumonia (HAP) drugs market?
  • What are the key market trends impacting the growth of the global hospital-acquired pneumonia (HAP) drugs market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global hospital-acquired pneumonia (HAP) drugs market?
  • What are the market opportunities and threats faced by the vendors in the global hospital-acquired pneumonia (HAP) drugs market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA.
  • What are the key outcomes of the five forces analysis of the global hospital-acquired pneumonia (HAP) drugs market? 

Technavio also offers customization on reports based on specific client requirement.


PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Pneumonia
  • Types of pneumonia

PART 06: Market landscape

  • Market overview
  • Market size and forecast

PART 07: Pipeline analysis

PART 08: Market segmentation by drug class

  • Antibacterial drug
  • Antiviral drugs
  • Others

PART 09: Geographical segmentation

  • HAP drugs market in Americas
  • HAP drugs market in EMEA
  • HAP drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Combination therapy for the treatment of HAP
  • Growing preference for accurate diagnosis of disease
  • Rising R&D for effective treatment against superbugs/MDR microorganisms

PART 13: Vendor landscape

  • Competitive landscape

PART 14: Key vendor analysis

  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.


Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases


Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts



  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis


  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your sample now!
  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?
  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis

Certified ISO 9001 : 2015

We are ISO recognized

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Customized Report as per your Business Needs

  • Our analysts will work directly with you and understand your needs
  • Get data on specified regions or segments, competitor and Vendors
  • Data will be formatted and presented as per your requirements
  • We offer $1000 worth of FREE customization at the time of purchase

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts
Enquire Before Buying
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>